10/2019 It is with great sadness we announce the loss of a dear friend and valued colleague, Mark Busgang. Mark passed on October 24th, 2019. He was a valued member of the IllumiSonics team and had a very meaningful impact on the company in his all-too-short time as CEO and President. Joining August 1st, 2019, Mark’s dedication and commitment to improving our world helped IllumiSonics set a path to success as a company. His wisdom and insights were much valued and will continue to guide our decisions.
Mark’s family and friends are in our thoughts as they go through this difficult time. He will be dearly missed. The IllumiSonics Board of Directors has appointed Dr. John Mackey as interim CEO, and we have started our search for a new CEO.
-Parsin Haji Reza, Bruce Johnson, John Mackey, Directors, IllumiSonics Inc. 10/2019 Professor Parsin featured in the weal (Waterloo Engineering Alumni Letter) magazine, October 2019 issue in the featured story: Ones to Watch: Seven researchers to keep an eye on as their soaring achievements continue to shake things up.
09/2019 Our current publication “All-optical Reflection-mode Microscopic Histology of Unstained Human Tissues” Scientific Reports 9, 13392 (2019) is in the top 5% of all research outputs ever tracked by Altmetric. Altmetric has tracked 13,528,047 research outputs across all sources so far.
09/2019 Congratulationsto Saad Abbasi for his new publication at Scientific Reports: “All-optical Reflection-mode Microscopic Histology of Unstained Human Tissues” Scientific Reports 9, 13392 (2019)
July 24, 2019 Waterloo, Ontario, July 24, 2019. Parsin H. Reza, founder and Chairman of the Board, is pleased to announce that Mark Busgang will join Illumisonics as President and CEO effective August 1, 2019.
“We are excited to have Mr. Busgang join our team” said Parsin H. Reza. “His experience in leading and growing businesses during his career brings us a dynamic and knowledgeable executive as we move from the discovery phase to pre-clinical and commercialization.”
“I am looking forward to working with the Illumisonics team” said Busgang. “Illumisonics and its PARS technology represent a breakthrough in diagnostic imaging and an incredible opportunity to change the field of diagnostic and surgical microscopy.”
About Mark Busgang: Mr. Busgang is the President and CEO of IllumiSonics Inc. Previously he was the COO of FCM Recycling Inc., responsible for the day to day operations at FCM. Concurrently with his mandate at FCM, Mr. Busgang was President of Busgang Consultants, focused on strategic planning and M&A. From 1998 to 2011 Mr. Busgang was Founder, President, and CEO of Warnex Ltd., a Laboratory Services company listed on the TSX. In 1993 Mark co-founded Theratechnologies Inc., a biotechnology company listed on the TSX, and served as Vice–President responsible for commercial operations. Prior to that, he served as President of Pharmetics Ltd, a leading Canadian contract manufacturer of pharmaceutical and nutraceutical products.
Mark has served on the boards of several private and public companies and institutions and charitable organizations. He was a finalist for the Ernst and Young Entrepreneur of the Year award in 2011 and is currently a member of YPO/WPO. He holds a B. Comm. degree in Accounting from Concordia University in Montreal and an MBA from the Martino School of Business at Fordham University in New York.